Hypofractionated Stereotactic Body Radiation Therapy as a Boost to the Prostate
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring prostate
Eligibility Criteria
Inclusion Criteria:
Histologically proven adenocarcinoma of the prostate
- Gleason score (2-10)
- Biopsy within six months of date of registration
- Patient age >18 years
Clinical stage (American Joint Committee on Cancer 7th Edition)
a. T-stage determined by physical exam (Digital Rectal Exam Required)
i. MRI findings (e.g. extracapsular extension) can be used to determine T-staging
b. N-stage determined using abdominopelvic CT scan and/or MRI
c. M-stage determined by physical exam, CT and/or MRI, and bone scan (must be M0, excepting Lymph nodes)
Please note: a SPECT bone scan including a CT of the abdomen and pelvis or an F18 Fluciclovine PET/CT fulfills protocol criteria for both the abdominopelvic CT and bone scan.
Patients must belong to one of the following risk groups:
- PSA > 20 and < 150 and/or
- Gleason 8-10 and/or
- > clinical T3a and/or
- Clinical N1
OR
- PSA 10 - 20 AND
- Gleason 7 AND
- Clinical T2b - T2c
- Patient is receiving, or planning to receive standard androgen deprivation therapy and initial IMRT to the prostate and positive or at-risk lymph nodes.
- Prostate volume greater than 20 cc and less than 100 cc
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Patient has agreed to complete questionnaires
- Signed IRB approved informed consent
- Patient eligible to have an MRI
- Must be able to tolerate the confinement of an MRI procedure
Exclusion Criteria:
- No prior prostate surgery (including TURP) or prostate cancer treatment with the exception of androgen deprivation therapy
- No prior radiotherapy to the pelvis
- No implanted hardware (including metal) or other material that would prohibit appropriate treatment planning or treatment delivery
- No metastatic disease, with the exception of lymph node positive disease
- No chemotherapy for a malignancy in the last 5 years.
- No history of an invasive malignancy (other than basal or squamous skin cancers) in the last 5 years.
- No heart pacemaker, No metallic foreign body (metal sliver) in the eye, No aneurysm clip in the brain
- No history of a pelvic or horseshoe kidney
- No diagnosis of inflammatory bowel disease
Sites / Locations
- Boston Medical Center
Arms of the Study
Arm 1
Experimental
Boost
CyberKnife Boost 21 Gy in 7 Gy per day, 3 fractions, Every other day